S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
4 stocks benefitting from NVIDIA's explosive growth
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Analysts boosted Snowflake stock, big firms are buying now
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
Is CRISPR Therapeutics the NVIDIA of gene editing?
First it was Tyson stock, now this food company is set to rally
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
6 reasons to buy Teva Pharmaceuticals stock sooner than later
Block's multiple ecosystems drive shares higher on 2024 outlook
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
4 stocks benefitting from NVIDIA's explosive growth
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Analysts boosted Snowflake stock, big firms are buying now
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
Is CRISPR Therapeutics the NVIDIA of gene editing?
First it was Tyson stock, now this food company is set to rally
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
6 reasons to buy Teva Pharmaceuticals stock sooner than later
Block's multiple ecosystems drive shares higher on 2024 outlook
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
4 stocks benefitting from NVIDIA's explosive growth
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Analysts boosted Snowflake stock, big firms are buying now
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
Is CRISPR Therapeutics the NVIDIA of gene editing?
First it was Tyson stock, now this food company is set to rally
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
6 reasons to buy Teva Pharmaceuticals stock sooner than later
Block's multiple ecosystems drive shares higher on 2024 outlook
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
4 stocks benefitting from NVIDIA's explosive growth
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Analysts boosted Snowflake stock, big firms are buying now
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
Is CRISPR Therapeutics the NVIDIA of gene editing?
First it was Tyson stock, now this food company is set to rally
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
6 reasons to buy Teva Pharmaceuticals stock sooner than later
Block's multiple ecosystems drive shares higher on 2024 outlook
NASDAQ:AKYA

Akoya Biosciences (AKYA) Stock Price, News & Analysis

$5.49
+0.14 (+2.62%)
(As of 02/23/2024 08:52 PM ET)
Today's Range
$5.26
$5.72
50-Day Range
$4.29
$6.06
52-Week Range
$3.04
$12.63
Volume
150,400 shs
Average Volume
219,735 shs
Market Capitalization
$269.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.60

Akoya Biosciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
56.6% Upside
$8.60 Price Target
Short Interest
Bearish
3.31% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.50mentions of Akoya Biosciences in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$33,600 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.47) to ($0.90) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.94 out of 5 stars

Medical Sector

608th out of 935 stocks

Analytical Instruments Industry

18th out of 28 stocks


AKYA stock logo

About Akoya Biosciences Stock (NASDAQ:AKYA)

Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.

AKYA Stock Price History

AKYA Stock News Headlines

Blue Chips And Billionaires Quietly Investing In "The New Oil"
They're as essential to the tech and AI revolutions as oil was to the industrial revolution. Known as rare earth elements or REEs, these relatively unheard of commodities are essential to semiconductor chips, renewable energy, electric vehicles, and more.
RNA Mar 2024 12.500 put
Blue Chips And Billionaires Quietly Investing In "The New Oil"
They're as essential to the tech and AI revolutions as oil was to the industrial revolution. Known as rare earth elements or REEs, these relatively unheard of commodities are essential to semiconductor chips, renewable energy, electric vehicles, and more.
Best Momentum Stocks to Buy for January 8th
BTIG Reaffirms Their Buy Rating on Akoya Biosciences (AKYA)
Analyst Ratings for Akoya Biosciences
See More Headlines
Receive AKYA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akoya Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/06/2023
Today
2/26/2024
Next Earnings (Confirmed)
3/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Analytical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:AKYA
Fax
N/A
Employees
369
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.60
High Stock Price Target
$11.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+56.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-70,640,000.00
Pretax Margin
-78.10%

Debt

Sales & Book Value

Annual Sales
$74.86 million
Book Value
$1.54 per share

Miscellaneous

Free Float
44,905,000
Market Cap
$269.45 million
Optionable
Optionable
Beta
1.48
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Mr. Brian McKelligon (Age 55)
    President, CEO & Director
    Comp: $1.15M
  • Dr. Nikolay Samusik Ph.D.
    Co-Founder
  • Dr. Yury Goltsev Ph.D.
    Co-Founder
  • Mr. John Frederick Ek (Age 48)
    CFO, Principal Financial Officer & Principal Accounting Officer
  • Dr. Frederic G. Pla Ph.D. (Age 65)
    Chief Operating Officer
    Comp: $445.27k
  • Priyam Shah
    Senior Director of Business Development & Investor Relations Strategy
  • Ms. Jennifer Kamocsay (Age 53)
    General Counsel
  • Mr. Paul Grass
    Senior Vice President of Sales
  • Dr. Niro Ramachandran Ph.D. (Age 49)
    Chief Business Officer
    Comp: $298.18k
  • Dr. Pascal Bamford Ph.D.
    Senior Vice President, Research & Development and Laboratory Operations














AKYA Stock Analysis - Frequently Asked Questions

Should I buy or sell Akoya Biosciences stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akoya Biosciences in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AKYA shares.
View AKYA analyst ratings
or view top-rated stocks.

What is Akoya Biosciences' stock price target for 2024?

5 Wall Street analysts have issued 1-year price targets for Akoya Biosciences' shares. Their AKYA share price targets range from $7.00 to $11.00. On average, they anticipate the company's stock price to reach $8.60 in the next twelve months. This suggests a possible upside of 56.6% from the stock's current price.
View analysts price targets for AKYA
or view top-rated stocks among Wall Street analysts.

How have AKYA shares performed in 2024?

Akoya Biosciences' stock was trading at $4.88 at the beginning of the year. Since then, AKYA stock has increased by 12.5% and is now trading at $5.49.
View the best growth stocks for 2024 here
.

When is Akoya Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024.
View our AKYA earnings forecast
.

How can I listen to Akoya Biosciences' earnings call?

Akoya Biosciences will be holding an earnings conference call on Monday, March 4th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Akoya Biosciences' earnings last quarter?

Akoya Biosciences, Inc. (NASDAQ:AKYA) posted its earnings results on Monday, March, 6th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.41) by $0.09. The firm earned $21.22 million during the quarter, compared to the consensus estimate of $20.85 million. Akoya Biosciences had a negative trailing twelve-month return on equity of 121.74% and a negative net margin of 78.14%. During the same quarter in the previous year, the company posted ($0.47) earnings per share.

What guidance has Akoya Biosciences issued on next quarter's earnings?

Akoya Biosciences issued an update on its FY 2024 earnings guidance on Monday, January, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $114.7 million-$115.9 million, compared to the consensus revenue estimate of $118.1 million.

When did Akoya Biosciences IPO?

(AKYA) raised $125 million in an initial public offering (IPO) on Friday, April 16th 2021. The company issued 6,600,000 shares at a price of $18.00-$20.00 per share. J.P. Morgan, Morgan Stanley, Piper Sandler and Canaccord Genuity served as the underwriters for the IPO.

Who are Akoya Biosciences' major shareholders?

Akoya Biosciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (2.87%), Parkman Healthcare Partners LLC (1.37%), Peddock Capital Advisors LLC (0.59%), Northern Trust Corp (0.45%), Charles Schwab Investment Management Inc. (0.42%) and Kent Lake Capital LLC (0.24%). Insiders that own company stock include Brian Mckelligon, Frederic Pla, Garry PhD Nolan, John Frederick Ek, Joseph Driscoll, Matthew Winkler, Niro PhD Ramachandran and Robert G Shepler.
View institutional ownership trends
.

How do I buy shares of Akoya Biosciences?

Shares of AKYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AKYA) was last updated on 2/26/2024 by MarketBeat.com Staff